Home >> Top News >> Qiagen launches QIAamp PowerFecal Pro DNA Kit

Qiagen launches QIAamp PowerFecal Pro DNA Kit

Print Friendly, PDF & Email

Oct. 8, 2018Qiagen announced the worldwide launch of the QIAamp PowerFecal Pro DNA Kit, for the extraction of high-quality DNA from fecal and gut samples.

The kit uses the company’s second-generation inhibitor removal technology and is intended for use with samples containing inhibitory substances commonly found in stool, such as polysaccharides, heme compounds, and bile salts. The company reports that improved IRT combined with more efficient bead beating and lysis chemistry yields high-quality DNA that can be used in downstream applications, including PCR, qPCR, and next-generation sequencing (16S and whole genome).

“Our understanding of the microbiome is expanding exponentially as we explore the interaction between microbes and the host,” Dominic O’Neil, director of microbiome product development at Qiagen, said in a press release. “As such, researchers need powerful tools to uncover the breadth of biodiversity in the gut and its interplay in the overall health of the host. The QIAamp PowerFecal Pro DNA Kit further advances Qiagen’s technology and market-leading position by taking an already strong product and making it even faster and more efficient for laboratories.” The kit can also be automated on the QIAcube sample prep instrument.


Check Also

Qiagen partners with DiaSorin, NeuMoDx

November 2018—Qiagen has introduced an automated, CE-marked workflow for its Quanti-Feron-TB Gold Plus Blood Collection Tubes and a novel DiaSorin Liaison Test on DiaSorin’s Liaison systems. The launch offers Liaison customers high-throughput detection with QFT-Plus as part of the system’s broad menu, and QFT-Plus users will gain an option for full automation of laboratory handling to support TB control efforts. Customers using the new latent TB detection workflow for Liaison systems will purchase the detec-tion components from DiaSorin and the blood collection tube kits from Qiagen. The test is available in Europe and other markets, with an expected U.S. release in 2019 and in China in 2020. In a separate release, Qiagen and NeuMoDx Molecular announced a strategic partnership to commercialize two fully integrated systems for automation of PCR test-ing. Under the agreement, Qiagen will initially distribute the NeuMoDx 288 (for high throughput) and NeuMoDx 96 (for mid-throughput) in Europe and other markets outside of the United States; NeuMoDx will cover the U.S.